Dual Antiplatelet Therapy for Acute Stroke and TIA: Current Best Practice and Emerging Strategies

Published: 07 November 2020

  • Views:

    Views Icon 88
  • Likes:

    Heart Icon 7

Overview

Full programme

  • Views:

    Views Icon 88
  • Likes:

    Heart Icon 7
Part 2 of 6

Secondary Prevention after Acute Minor Stroke or TIA: Understanding the Ongoing Risk

Peter Rothwell

Overview

This educational symposium was first broadcast in the joint European Stroke Organisation and World Stroke Organization (ESO-WSO 2020) Virtual Conference held 7-9 November.

 

The programme focuses upon emerging data and best practice in the use of antiplatelet therapy for the treatment of Acute Stroke and TIA

 

EBAC Accreditation

The programme was supported by an unrestricted educational grant from AstraZeneca.

Learning Objectives

  • To Highlight the Continued High Unmet Need for Strategies to Prevent Stroke or Death for Patients Experiencing Acute Stroke or TIA
  • To Outline the Guidelines on the Use of Dual Antiplatelet Therapy for Patients Presenting with Acute Stroke or TIA
  • To Examine Recent Evidence from Clinical Trials on Novel Strategies for Improving Outcomes for Patients Presenting with Acute Stroke or TIA and How These Data and Insights Can Be Applied in Clinical Practice

More from this programme

Part 1

Chairperson’s Welcome and Introduction

Part 2

Secondary Prevention after Acute Minor Stroke or TIA: Understanding the Ongoing Risk

Part 3

Current Best Practice: Evidence-Based Antiplatelet Therapy for Secondary Stroke Prevention

Part 4

Evolving Role of Dual Antiplatelet Therapy for Stroke Prevention: Advancing Best Practice for Patients at High Risk

Part 5

Clinical Decision Making for the Patient Presenting with Acute Stroke

Part 6

Q&A and Summary

Faculty Biographies

Peter Rothwell

Peter Rothwell

Peter M Rothwell is Founding Director, at the Wolfson Centre for Prevention of Stroke and Dementia, Action Research Professor of Neurology, at the University of Oxford, UK

View full profile